May 19, 2026 | Takeda $885M Antitrust Verdict; Bimzelx Beats Skyrizi in PsA Head-to-Head

Takeda hit with $885M pay-for-delay verdict over generic Amitiza delay. UCB's Bimzelx beats AbbVie's Skyrizi 49% vs 38% on ACR50 in PsA head-to-head. Trump bought up to $680K in Eli Lilly stock while admin promoted obesity drugs. Maryland caps Ozempic payments. Amgen Tavneos linked to 20 deaths in Japan. Relay zovegalisib Phase 2 data beats expectations. Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Takeda, Amitiza, pay-for-delay, antitrust, UCB, Bimzelx, bimekizumab, AbbVie, Skyrizi, risankizumab, psoriatic arthritis, Trump, Eli Lilly, Zepbound, Mounjaro, obesity drugs, Maryland, Ozempic, Novo Nordisk, semaglutide, Amgen, Tavneos, avacopan, Relay Therapeutics, zovegalisib, BioMarin, ENPP1, Roche, Xofluza, Regeneron, Parabilis, Novartis, Porton, CDMO, Tarsier Pharma, drug pricing, Lilly, AstraZeneca